
Clinical TrialNov 17, 2026, 04:46 PM
Biogen Alzheimer's Drug Diranersen Shows 38% Clinical Decline Slowing at 2 Years
AI Summary
Biogen Inc. announced new Phase 2 CELIA study data for diranersen, an investigational Alzheimer's therapy targeting tau. Two-year results showed diranersen slowed clinical decline, with the 60 mg twice-yearly regimen demonstrating the most significant benefits across multiple measures, including a 38% slowing on CDR-SB. The therapy was generally well-tolerated, with no new safety signals. These findings support the continued development of diranersen for early Alzheimer's disease.
Key Highlights
- Diranersen slowed clinical decline by 38% on CDR-SB at two years (Week 96) with the 60 mg twice-yearly regimen.
- Greater slowing of clinical decline observed across 5 of 6 measures at two years compared to 18 months in the 60 mg dose group.
- Clinical benefits were observed across all doses studied, with the 60 mg dose group showing compelling efficacy.
- The 60 mg twice-yearly regimen demonstrated a 1.09-point treatment difference on CDR-SB at Week 96.
- Diranersen was generally well tolerated through two years with no new safety signals.
- Data presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference.
- Biogen exercised a license option with Ionis Pharmaceuticals in December 2019 for diranersen.
Price Impact
More from BIIB